243 related articles for article (PubMed ID: 18305454)
1. How should adverse events be reported in US clinical trials?: ethical considerations.
Shamoo AE; Katzel LI
Clin Pharmacol Ther; 2008 Aug; 84(2):275-8. PubMed ID: 18305454
[TBL] [Abstract][Full Text] [Related]
2. Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment.
Caulfield T
Health Law Rev; 2005; 13(2-3):58-61. PubMed ID: 16459415
[No Abstract] [Full Text] [Related]
3. Protection of children and risks with medical devices.
Maloney DM
Hum Res Rep; 2004 Dec; 19(12):3. PubMed ID: 15810178
[No Abstract] [Full Text] [Related]
4. Congress responds to the IOM drug safety report--in full.
Psaty BM; Korn D
JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
[No Abstract] [Full Text] [Related]
5. The research subject as identified problem.
Wolpe PR
Am J Bioeth; 2011 Apr; 11(4):1-2. PubMed ID: 21480061
[No Abstract] [Full Text] [Related]
6. Extend the reach of institutional review boards first, then strengthen their depth.
Spike J
Am J Bioeth; 2008 Nov; 8(11):11-2. PubMed ID: 19061097
[No Abstract] [Full Text] [Related]
7. IOM advises FDA on ethics in postmarket safety trials.
Kuehn BM
JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
[No Abstract] [Full Text] [Related]
8. Ethical issues during the conduct of clinical trials.
Silverman H
Proc Am Thorac Soc; 2007 May; 4(2):180-4; discussion 184. PubMed ID: 17494728
[TBL] [Abstract][Full Text] [Related]
9. Next steps in clinical trial redesign.
Nicholas J
J Natl Cancer Inst; 2012 Jan; 104(2):90-2. PubMed ID: 22215851
[No Abstract] [Full Text] [Related]
10. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.
Bunney WE; Azarnoff DL; Brown BW; Cancro R; Gibbons RD; Gillin JC; Hullett S; Killam KF; Kupfer DJ; Krystal JH; Stolley PD; French GS; Pope AM
Arch Gen Psychiatry; 1999 Apr; 56(4):349-52. PubMed ID: 10197830
[No Abstract] [Full Text] [Related]
11. Expanding disclosure of conflicts of interest: the views of stakeholders.
Brody BA; Anderson C; McCrary SV; McCullough L; Morgan R; Wray N
IRB; 2003; 25(1):1-8. PubMed ID: 12833897
[No Abstract] [Full Text] [Related]
12. IOM: overhaul drug safety monitoring.
Kuehn BM
JAMA; 2006 Nov; 296(17):2075-6. PubMed ID: 17077364
[No Abstract] [Full Text] [Related]
13. [The impact of researchers loyal to Big Pharma on the ethics and quality of clinical trials in Latin America].
Ugalde A; Homedes N
Salud Colect; 2015 Mar; 11(1):67-86. PubMed ID: 25853831
[TBL] [Abstract][Full Text] [Related]
14. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
15. Recurrent issues in the review of medical research on human subjects.
Moore DL
Albany Law J Sci Technol; 1991; 1():1-33. PubMed ID: 16296123
[No Abstract] [Full Text] [Related]
16. Reporting standards for adverse events after medical device use in the peripheral vascular system.
Ouriel K; Fowl RJ; Davies MG; Forbes TL; Gambhir RP; Morales JP; Ricci MA;
J Vasc Surg; 2013 Sep; 58(3):776-86. PubMed ID: 23972246
[No Abstract] [Full Text] [Related]
17. Children need more protection in clinical trials, says IOM. Panel concludes that current regulations are misapplied, but stops short of calling for strict enforcement.
Ault A
Lancet; 2004 Apr; 363(9415):1119. PubMed ID: 15068011
[No Abstract] [Full Text] [Related]
18. Evaluation in health promotion: thoughts from inside a human research ethics committee.
Allen J; Flack F
Health Promot J Austr; 2015 Dec; 26(3):182-185. PubMed ID: 26538345
[TBL] [Abstract][Full Text] [Related]
19. Researchers push back against overhauling clinical trials.
Jenks S
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25122733
[No Abstract] [Full Text] [Related]
20. Making clinical trials safer for human subjects.
Baram M
Am J Law Med; 2001; 27(2-3):253-82. PubMed ID: 11467112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
